 HOUSTON, June 29, 2021 PRNewswire -- CNS Pharmaceuticals, Inc. NASDAQ: CNSP CNS or the Company, a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that the U.S. Food and Drug Administration FDA granted Fast Track Designation for its lead investigational drug, Berubicin, for the treatment of patients with recurrent glioblastoma multiforme GBM. As previously reported, the Company has also received Orphan Drug Designation from the FDA for Berubicin for the treatment of patients with recurrent GBM. 